A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

Three agents are approved, and more studies are underway ...

Myasthenia gravis is a chronic autoimmune disorder that inhibits communication between nerve cells and muscles, causing muscle weakness. It has no cure, but several treatment options can help improve ...

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function. “Research has ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

After years of a therapeutic drought in generalized myasthenia gravis (gMG), new targeted therapies are finally providing options for rapidly effective and safe treatment. This rare autoimmune ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and Drug ...

Overactivation of the immune system is a potential serious adverse event (AE) following immune checkpoint inhibition (ICI) treatment for any of several cancers in the first and second line; among ...

Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and ...